Boston Scientific (BSX) EBT (2009 - 2026)

Boston Scientific has disclosed EBT across 18 years of filings, most recently posting $1.2 billion for Q1 2026.

• EBT for Q1 2026 came in at $1.2 billion, up 44.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 billion (up 50.95% YoY), and the FY2025 annual result was $3.4 billion, up 48.33% from the prior year.
• EBT came in at $1.2 billion for Q1 2026 at Boston Scientific, up from $700.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.2 billion in Q1 2026 to a low of $156.0 million in Q1 2022.
• The 5-year median for EBT is $585.0 million (2024), against an average of $585.6 million.
• Peak annual rise in EBT reached 232.77% in 2022, while the deepest fall reached 52.0% in 2022.
• Boston Scientific's EBT stood at $396.0 million in 2022, then increased by 27.53% to $505.0 million in 2023, then gained by 15.84% to $585.0 million in 2024, then advanced by 19.66% to $700.0 million in 2025, then jumped by 66.0% to $1.2 billion in 2026.
• The last three EBT figures came in at $1.2 billion (Q1 2026), $700.0 million (Q4 2025), and $939.0 million (Q3 2025), per Business Quant data.